Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Semin Oncol ; 45(1-2): 27-33, 2018 01.
Article in English | MEDLINE | ID: mdl-30318081

ABSTRACT

The rational combination of recombinant IFN-α2b and IFN-γ resulted in a new formulation of interferons (HeberFERON) with improved pharmacodynamics. In basal cell carcinomas HeberFERON produces a more rapid antitumor effect and results in a larger number of complete responses. In patients with glioblastoma multiforme, the administration of HeberFERON after surgery and radiotherapy results in an estimated overall survival of 19 months. Patients with stage III or IV renal cell carcinoma also appear to benefit from the intravenous administration of HeberFERON, with prolongation of survival and good quality of live. HeberFERON offers a promising alternative formulation of interferons for the treatment of cancer with a very favorable safety profile.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Interferon-alpha/therapeutic use , Interferon-gamma/therapeutic use , Neoplasms/drug therapy , Gene Expression Regulation, Neoplastic , Humans , Interferon alpha-2 , Interferon-alpha/administration & dosage , Interferon-alpha/pharmacokinetics , Interferon-gamma/administration & dosage , Interferon-gamma/pharmacokinetics , Neoplasms/genetics , Neoplasms/metabolism , Proteome/metabolism , Quality of Life , Survival Analysis , Treatment Outcome
2.
BMC Pharmacol Toxicol ; 17(1): 58, 2016 12 07.
Article in English | MEDLINE | ID: mdl-27923408

ABSTRACT

BACKGROUND: More potent antitumor activity is desired in Interferon (IFN)-treated cancer patients. This could be achieved by combining IFN alpha and IFN gamma. The aim of this work was to characterize the pharmacokinetics and pharmacodynamics of a novel formulation containing a co-formulated combination of IFNs alpha-2b and gamma (CIGB-128-A). METHODS: A group of nine healthy male subjects received intramuscularly 24.5 × 106 IU of CIGB-128-A. IFN concentrations were evaluated for 48 h. Serum neopterin, beta2-microglobulin (ß2M) and 2'-5' oligoadenylate synthetase (2'-5' OAS), classical IFN-inducible serum markers, were measured during 192 h by enzyme immunoassay and body temperature was used as pharmacodynamic variable as well. RESULTS: Concerning pharmacokinetics, serum IFNs' profiles were better fitted to a mono-compartmental model with consecutive zero order and first order absorption, one bioavailability value. No interferences by simultaneous administered IFNs were observed in their typical similar systemic profiles. Neopterin and ß2M time profiles showed a delay that was efficiently linked to pharmacokinetics by means of a zero order absorption rate constant. Neopterin level was nine-fold higher than initial values, 48 h post-administration, an increment not described before. At this time, mean serum ß2M peaked around the double from baseline. Serum concentrations of the enzyme 2'-5' OAS was still elevated on the 8 day post-injection. The formulation was well tolerated. Most frequent adverse reactions were fever, headache, arthralgia and lymphopenia, mostly mild. CONCLUSIONS: The administration of co-formulated IFN alpha-2b and IFN gamma likely provides improved pharmacodynamic properties that may be beneficial to treat several malignancies. TRIAL REGISTRATION: Cuban Public Registry of Clinical Trials RPCEC00000118 , May 24, 2011.


Subject(s)
Drug Compounding/methods , Interferon-alpha/administration & dosage , Interferon-alpha/pharmacokinetics , Interferon-gamma/administration & dosage , Interferon-gamma/pharmacokinetics , Adult , Drug Combinations , Healthy Volunteers , Humans , Injections, Intramuscular , Interferon alpha-2 , Male , Recombinant Proteins/administration & dosage , Recombinant Proteins/pharmacokinetics , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...